Female Infertility Diagnosis Market (By Test: Ovarian Reserve Testing, Hormone Testing, Hysterosalpingography, Other Tests) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2024-2033

Female Infertility Diagnosis Market Size and Growth

The global female infertility diagnosis market size was estimated at USD 4.48 billion in 2023 and it is expected to surpass around USD 10.25 billion by 2033, poised to grow at a CAGR of 8.63% from 2024 to 2033. The female infertility diagnosis market is a vital segment within the broader reproductive health industry, focusing on the identification and assessment of factors contributing to female infertility.

Key Pointers

• The Europe led the market with the largest market share of 36% in 2023.
• By Test, the ovarian reserve testing segment commanded the largest market share of 44% and is estimated to expand the fastest CAGR from 2024 to 2033.

Female Infertility Diagnosis Market Growth Factors

The growth of the female infertility diagnosis market is primarily driven by the technological advancements play a crucial role, as innovations such as high-resolution imaging techniques, sophisticated genetic testing, and advanced hormonal assays have significantly improved diagnostic accuracy and efficiency. Additionally, the rising prevalence of infertility, influenced by lifestyle changes, delayed childbearing, and various medical conditions, has led to an increased demand for diagnostic services. Increased awareness and education about reproductive health have also contributed to market expansion, as more women seek early diagnosis and treatment. Furthermore, improved healthcare access and the proliferation of specialized fertility clinics have made diagnostic procedures more widely available, further fueling market growth.

What are the Trends in Female Infertility Diagnosis Market?

• Integration of AI and Machine Learning: The incorporation of artificial intelligence (AI) and machine learning into diagnostic tools is enhancing the accuracy and efficiency of infertility assessments, enabling more personalized and precise diagnoses.
• Rise of Home Diagnostic Kits: There is a growing trend towards the development and use of at-home diagnostic kits, allowing women to perform initial fertility tests privately and conveniently before seeking professional medical advice.
• Expansion of Genetic Testing: Advances in genetic testing are becoming more prevalent, with increased focus on identifying genetic factors and abnormalities that contribute to infertility, offering a more comprehensive understanding of reproductive health.
• Enhanced Imaging Technologies: The use of advanced imaging technologies, such as high-resolution ultrasound and 3D imaging, is on the rise, providing more detailed and accurate visualization of reproductive organs and conditions.
• Increased Focus on Preventive Diagnostics: There is a growing emphasis on preventive diagnostics, with more proactive approaches being adopted to identify and address infertility issues before they become more serious.

What are the Key Challenges Faced by Female Infertility Diagnosis Market?

• Limited Awareness and Education: Despite growing awareness, there are still gaps in public knowledge about infertility and available diagnostic options, which can lead to underutilization of diagnostic services and delayed treatment.
• Healthcare Disparities: Differences in healthcare access and quality across various geographic regions can result in unequal availability of diagnostic services, with underserved areas experiencing significant gaps in infertility care.
• Data Privacy Concerns: The use of sensitive personal health data in diagnostic procedures raises concerns about data privacy and security, requiring robust measures to protect patient information and comply with data protection regulations.
• Technological Complexity: The increasing complexity of diagnostic technologies can pose challenges for both healthcare providers and patients, necessitating ongoing training and support to ensure effective use and accurate results.
• Integration with Existing Systems: Integrating new diagnostic tools and technologies with existing healthcare systems and workflows can be challenging, potentially affecting the efficiency and effectiveness of infertility diagnosis and treatment.

What is the Contribution of Europe to Female Infertility Diagnosis Market?

The female infertility diagnosis market in Europe held the largest share of 36%, fueled by growing demand for infertility diagnosis and treatments. A July 2024 report by the European Society of Human Reproduction and Embryology (ESHRE) revealed an increase in IVF cycles among European women, indicating a trend towards greater utilization of assisted reproductive technologies to address infertility.

In the UK, the market is experiencing notable growth, driven by lifestyle factors contributing to fertility issues. Smoking, excessive alcohol consumption, poor diet, lack of exercise, and high stress levels negatively impact fertility by disrupting hormone levels, sperm quality, ovulation, and overall reproductive health.

North America

In 2023, the female infertility diagnosis market in North America is expected to hold a significant share. The market growth in this region is driven by rising infertility rates and the increasing need for external support. The decline in fertility rates, particularly in Canada, has notably influenced market expansion. According to Statistics Canada, published in September 2022, the fertility rate in Canada decreased to 1.43 children per woman in 2021, well below the replacement level of 2.1 children per woman.

Asia Pacific

The female infertility diagnosis market in the Asia Pacific region is witnessing significant growth due to heightened healthcare awareness and collaborative initiatives. A July 2023 expert meeting on population aging and low fertility addressed the implications of these demographic trends for sustainable development. This meeting, which involved experts, policymakers, and stakeholders, emphasized the impact of an aging population on societies, economies, and healthcare systems in the Asia-Pacific region.

In Japan, the female infertility diagnosis market is poised for rapid growth, driven by rising demand for fertility detection and treatments. Factors such as delayed marriages, career pressures, and declining birth rates have led to the emergence of fertility start-ups addressing the growing need for reproductive assistance.

Test Insights

In 2023, the ovarian reserve testing segment commanded the largest market share of 44% and is projected to experience the highest growth rate over the forecast period. This leading position is attributed to the rise in reproductive health concerns among women. Ovarian reserve testing is essential for evaluating a woman’s fertility potential by assessing the quantity and quality of her remaining eggs. It is particularly relevant for women contemplating delayed childbearing, those with a family history of early menopause, or individuals undergoing treatments like chemotherapy that could affect ovarian function.

Additionally, ovarian reserve testing is crucial for assisted reproductive technologies (ART), including in vitro fertilization (IVF). Evaluating ovarian reserve helps customize treatment plans and predict responses to stimulation. By analyzing markers such as anti-Müllerian hormone (AMH) levels, antral follicle count (AFC), and follicle-stimulating hormone (FSH) levels, healthcare providers can offer personalized advice, enabling women to make informed decisions about their reproductive options.

Who are the Top Manufactures in Female Infertility Diagnosis Market?

• PFCLA
• Mayo Foundation for Medical Education and Research (MFMER)
• Cleveland Clinic
• Apricity Fertility UK Limited
• King’s Fertility Limited
• Dallas IVF
• Midwest Fertility Specialists
• Europe IVF
• Care Fertility
• Aspire Fertility

Recent Developments

• In February 2024, Health Minister Robin Swann announced that publicly funded IVF treatment in Northern Ireland will now cover one full cycle for eligible women. This decision represents a major advancement in improving access to fertility treatments for couples facing infertility challenges. The coverage is expected to ease the financial strain associated with IVF procedures, which are often expensive and may require multiple cycles to achieve successful outcomes.
• In February 2024, Femasys obtained FDA clearance for its FemaSeed product, marking a significant breakthrough in infertility treatment. FemaSeed offers a novel alternative to traditional methods such as in vitro fertilization (IVF), positioning itself as a first-line treatment option for couples with infertility issues. This development provides a less invasive and more accessible solution compared to conventional approaches.
• In August 2023, Main Line Fertility expanded its services through the integration of Sincera Reproductive Medicine. This merger is a notable advancement in reproductive medicine, combining the strengths of two esteemed fertility clinics to deliver enhanced care and expertise to patients seeking fertility treatments.

Female Infertility Diagnosis Market Segmentation:

By Test

• Ovarian Reserve Testing
• Hysterosalpingography
• Hormone testing
• Other Tests

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa